Neurological manifestations of coronavirus disease 2019 (COVID-19) are now well recognized, ranging from mild symptoms such as anosmia to severe complications including stroke and encephalopathy. However, cranial neuropathies are typically described as post-infectious, immune-mediated phenomena—most notably in the context of Miller Fisher syndrome or Guillain–Barré variants. This case report from the Journal of Medical Case Reports highlights a distinctly different mechanism: cranial neuropathy occurring during the acute infectious phase with direct viral detection in cerebrospinal fluid (CSF) .

A 53-year-old woman presented with acute headache, right ptosis, diplopia, and trigeminal sensory loss, notably without any respiratory or systemic COVID-19 symptoms. Neurologic examination localized deficits to cranial nerves III and V, raising concern for vascular, infectious, or cavernous sinus pathology.

Extensive neuroimaging—including MRI, MRA, and MRV—was unrevealing. However, SARS-CoV-2 PCR testing returned positive in both nasopharyngeal and CSF samples, a rare and critical finding. CSF analysis showed mildly elevated protein but no pleocytosis, and there was no radiographic or clinical evidence of alternative etiologies.

The patient was treated with remdesivir and corticosteroids, with subsequent improvement in cranial neuropathy.

This case is notable for several reasons:

Absence of respiratory symptoms, emphasizing atypical presentations
Concurrent CSF positivity, supporting direct viral neuroinvasion
Isolated cranial neuropathy, rather than typical post-infectious syndromes

While most neurological complications of COVID-19 are thought to be immune-mediated, this case supports multiple potential mechanisms, including:

Direct viral invasion of neural tissue
Immune-mediated neuronal injury
Microvascular dysfunction (especially relevant given comorbid diabetes)

Importantly, the detection of SARS-CoV-2 in CSF strongly favors true neurotropism, rather than secondary immune effects alone .

Clinical Take-Home Message (Pearl):

COVID-19 should be considered in patients presenting with acute cranial neuropathies—even in the absence of respiratory symptoms—particularly when diagnostic workup is otherwise unrevealing.

Question:

What is the most likely mechanism explaining cranial neuropathy in this patient?

A. Post-infectious autoimmune demyelination (Miller Fisher syndrome)
B. Microvascular ischemia from diabetes alone
C. Direct viral invasion of cranial nerves by SARS-CoV-2
D. Medication-induced cranial neuropathy

Correct Answer:

C. Direct viral invasion of cranial nerves by SARS-CoV-2

The key distinguishing feature in this case is the presence of SARS-CoV-2 RNA in the cerebrospinal fluid, which is rarely demonstrated in COVID-19 neurological syndromes. This finding supports direct neuroinvasion, likely via hematogenous spread or retrograde neuronal transport.  While immune-mediated mechanisms (e.g., molecular mimicry) are more commonly implicated in COVID-19–related neuropathies, they typically occur days to weeks after infection and are not associated with viral detection in CSF. In contrast, this case demonstrates acute-phase neurological involvement with virologic confirmation, making direct viral toxicity the most plausible mechanism.